Results 111 to 120 of about 2,472,934 (283)

Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis. [PDF]

open access: yesERJ Open Res, 2023
Chalmers JD   +7 more
europepmc   +1 more source

Credit risk regulation in the Czech Republic after Basel II [PDF]

open access: yes
In this year, new capital adequacy regulation, known as Basel II, came into force. Based on these rules, two directives of the European Parliament and of the Council have been revised and the new decree of Czech National Bank has come into force.
Vodová, Pavla
core   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Collateral and its Determinants: Evidence from Vietnam [PDF]

open access: yes
This paper analyses the determinants of collateral in loans granted to entrepreneurs and consumers. We use cross-sectional data on more than 39,000 bank loans raised by Vietnamese borrowers between 2006 and 2009.
Dinh, Thanh   +2 more
core  

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

open access: yesMolecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed   +10 more
wiley   +1 more source

Benefit-Risk Assessment in Drug Development

open access: yes, 2012
Denne afhandling omhandler udviklingen, afprøvningen og brugen af en metode for datadreven benefit-risk evaluering. Metoden blev udviklet som iterativ proces og er skræddersyet til benefit-risk evaluering af kliniske data. Fokus har været på tre afgørende aspekter: (i) gennemsigtighed, (ii) klinisk signifikans og (iii) visualisering.Metoden er ...
Sarac, Sinan   +3 more
openaire   +3 more sources

The value of information in biosecurity risk-benefit assessment: an application to red imported fire ants [PDF]

open access: yes
Policy makers are confronted daily with uncertainty, especially in complex areas like biosecurity. One way to improve decision-making and reduce uncertainties is to collect more information.
Kompas, Tom, Ward, Michael B.
core   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

open access: yesMolecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto   +8 more
wiley   +1 more source

Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years. [PDF]

open access: yesVaccine X, 2023
Yogurtcu ON   +5 more
europepmc   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy